Show simple item record

FieldValueLanguage
dc.contributor.authorAbed, Hany S
dc.contributor.authorFulcher, Jordan
dc.contributor.authorKilborn, Michael J
dc.contributor.authorKeech, Anthony C
dc.date.accessioned2017-05-02
dc.date.available2017-05-02
dc.date.issued2016-04-10
dc.identifier.citationAbed HS, Fulcher J, Kilborn MJ, Keech AC. Inappropriate sinus tachycardia: focus on ivabradine. Internal Medicine Journal 2016; 46(8): 875–883.en_AU
dc.identifier.urihttp://hdl.handle.net/2123/16696
dc.description.abstractInappropriate sinus tachycardia (IST) is an incompletely understood condition characterised by an elevation in heart rate (HR) accompanied by wide ranging symptoms, in the absence of an underlying physiological stimulus. The condition often takes a chronic course with significant adverse effects on quality of life. Currently there is no effective treatment for IST. Beta-blockers, generally considered the cornerstone of treatment, are often ineffective and poorly tolerated. Ivabradine is a novel sinus node If "funny current" inhibitor which reduces the HR. It has been approved for the treatment of beta-blocker refractory chronic systolic heart failure and chronic stable angina, but more recently shown promise in the treatment of IST. This review provides an overview of IST prevalence and mechanisms, followed by an examination of the evidence for the role and efficacy of ivabradine in the treatment of IST.en_AU
dc.language.isoen_AUen_AU
dc.publisherRACPen_AU
dc.subjectivabradineen_AU
dc.subjectsinus tachycardiaen_AU
dc.titleInappropriate sinus tachycardia: focus on ivabradineen_AU
dc.typeArticleen_AU
dc.subject.asrcECGen_AU
dc.type.pubtypePost-printen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.